Peran Terlipressin pada Penyakit Hati Kronik

Authors

  • Decky Andrea Universitas Sam Ratulangi
  • Luciana Rotty Universitas Sam Ratulangi

DOI:

https://doi.org/10.35790/msj.v3i1.33784

Abstract

Abstract: Chronic liver disease is a progressive impairment of liver function. It is caused by non-alcoholic fatty liver, viral infection of the liver, excessive alcohol consumption, metabolic diseases such as galactosemia, autoimmune disease, and the influence of chemicals. Complications that are often found are esophageal variceal bleeding, hepatorenal syndrome, and refractory ascites. Terlipressin, which is a vasopressin analogue, is currently widely used in developed countries because it has been shown to improve survival of patients with esophageal varices, hepatorenal syndrome, and refractory ascites. Terlipressin is the current standard therapy for esophageal variceal bleeding in countries where it is available.

Keywords: chronic liver disease; terlipressin

  

Abstrak: Penyakit hati kronis (PHK) adalah gangguan fungsi hati yang terjadi secara progresif. Peyakit hati kronis di sebabkan oleh non-alcoholic fatty liver, infeksi virus pada hati, konsumsi alkohol berlebihan, peyakit metabolik seperti galaktosemia, penyakit autoimun, dan pengaruh bahan kimia. Komplikasi yang sering ditemukan pada PHK ialah perdarahan varises esofagus, sindrom hepatorenal, dan asites refrakter. Terlipressin yang merupakan analog vasopressin saat ini banyak di pakai di negara maju karena terbukti dapat meningkatkan kelangsungan hidup pasien perdarahan varises esofagus, sindrom hepatorenal, dan asites refrakter. Dewasa ini terlipressin telah menjadi terapi standar perdarahan varises esofagus di negara-negara di mana obat ini tersedia.

Kata kunci: penyakit hati kronik; terlipressin

Downloads

Published

2021-05-04

How to Cite

Andrea, D., & Rotty, L. (2021). Peran Terlipressin pada Penyakit Hati Kronik. Medical Scope Journal, 3(1), 24–32. https://doi.org/10.35790/msj.v3i1.33784

Issue

Vol. 3 No. 1 (2021): Medical Scope Journal

Section

Articles

License

COPYRIGHT

 

Authors who publish with this journal agree to the following terms:

Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.

Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.

Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).